Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (25.17%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (36.38%) | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (15.53%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 87.65 | |
Free Cash Flow per Share |
0.00 | 0.00 | (8.66) | (1.83) | |
Free Cash Flow |
— | (143.40) | (106.18) | (107.53) | |
Capital Expenditures |
— | (9.63) | (7.28) | (10.37) | |
| Other line items | |||||
Cash ROIC |
0.00% | (123.78%) | (54.04%) | (18.77%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 133.97 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 441.16 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 51.98% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 53.67% | |
Share Based Compensation of Revenue |
— | — | — | 7.14% | |
Interest Coverage |
— | — | — | (78.28) | |
Operating CF/Net income |
— | 0.00 | 0.00 | 1.97 | |
Depreciation/Fixed assets |
— | 0.67 | 0.65 | 0.54 | |
Capex/Depreciation |
— | (1.38) | (1.06) | (1.44) | |
Revenue per Share |
0.00 | — | 0.00 | 1.44 | |
Operating CF per Share |
0.00 | 0.00 | (8.07) | (1.66) | |
Capex per Share |
0.00 | 0.00 | (0.59) | (0.18) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.12 |
Columns are period end dates